The stock rallied 8% per cent to Rs 243 in the intra-day deals today, and was quoting at its highest level since February 14, 2020 on the BSE
Here's a look at the top stocks that may remain in focus today
Today, a total of 31 companies including Voltas, Jubilant Life Sciences, and Metropolis Healthcare, are scheduled to announce their March quarter results
If Nifty is unable to surpass its previous swing high of 9584.5, we can expect profit booking at higher levels
On the technical charts, Bank Nifty made a 'Double Bottom' pattern at around 17,000 levels on May 22, which indicated that a rally was bound to happen, says Nandish Shah of HDFC Securities
Pricing pressure in US, lockdown may dent near-term prospects
The gains come after huge selling pressure and consequent under-performance of banking stocks since the start of March
Rs 1,000-cr rights issue, lower costs to help pare Rs 2,500-cr debt
The rally has been underpinned by sharp gains in banking stocks. The Bank Nifty index has rallied 9.9 per cent in the past two sessions
According to the brokerage, companies with debt/Ebitda of less than 0.7 are at low risk
The Finance Act, 2015, had introduced Section 9A to encourage fund management activity from India and provide a safe harbour to onshore managements of offshore funds
BSE Sensex surged 595 points or 1.88 per cent to 32,200.59 levels, with L&T (up 6 per cent) being the top gainer and ITC (down around 1 per cent) the biggest loser
All that happened in the markets today
The Board approved to raise fresh long-term borrowing to meet the company's financial needs during financial year 2020-21, for a sum not exceeding in the aggregate Rs 200 crore
NSE's Nifty50 index ended at 9,315, up 286 points or 3 per cent.
The fund-raising will be used to meet the Haridwar-based company's working capital requirements and strengthen the supply chain network
The company announced stock split plan to make the stock more affordable for the small retail investors and increase liquidity.
As the lockdown restrictions eased gradually, Dabur has been at the forefront of delivering authentic Ayurvedic solutions to meet the emerging Health Care needs of consumers in the post-COVID market.
The company said in the near term, the demand for the Company's product will be impacted which will have some impact on the results of the Company in the short-term.
Net profit, too, saw a 37 per cent YoY fall to Rs 399.8 crore, against estimates of Rs 950-1,000 crore.